CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Nova is the first company to achieve psilocybin orphan drug
designation
in both the U.S. and European Union for the treatment of
fragile X syndrome, the leading genetic cause of symptoms
related to autism spectrum disorder.

This provides us with financial benefits, market exclusivity,
research assistance and access to grants.

FDA EMA

 

Autism Spectrum Disorder and Fragile X Syndrome Observational Study

 

Learn More

Latest News

Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada

Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome

Vancouver, British Columbia – November 30, 2022 Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders ...

 

Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial

Vancouver, British Columbia – November 17, 2022 Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has entered into a research services agreement with KGK Sciences Inc. (KGK), a wholly owned subsidiary of Wellness Digital Science Inc. (NEO: MEDI) (OTC: KONEF)